AMAG Pharmaceuticals, Inc. Sustainability Profile
AMAG Pharmaceuticals, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States. Founded in 1981, the company has established itself as a leader in developing innovative therapies primarily focused on women's health, maternal health, and supportive care. With a strong presence in North America and expanding operations in international markets, AMAG is dedicated to addressing unmet medical needs. The company’s core products, including treatments for iron deficiency anaemia and preterm labour, are distinguished by their commitment to safety and efficacy. AMAG's notable achievements include a robust pipeline of therapies that leverage cutting-edge research and development. As a trusted name in the biopharmaceutical sector, AMAG Pharmaceuticals continues to enhance patient outcomes and solidify its market position through strategic partnerships and a focus on innovation.
DitchCarbon Score
How does AMAG Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
AMAG Pharmaceuticals, Inc.'s score of 41 is higher than 60% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
AMAG Pharmaceuticals, Inc.'s reported carbon emissions
In 2024, AMAG Pharmaceuticals, Inc. reported total carbon emissions of approximately 1,064,800,000 kg CO2e. This figure includes 92,200,000 kg CO2e from Scope 1 emissions, while Scope 2 emissions were recorded at 0 kg CO2e. Additionally, Scope 3 emissions from purchased goods and services amounted to about 972,600 kg CO2e. The company has shown a commitment to transparency in its emissions reporting, disclosing data across all three scopes. However, there are currently no specific reduction targets or initiatives outlined in their climate commitments. The emissions data is cascaded from AMAG Pharmaceuticals, Inc. as a current subsidiary of Azurity Pharmaceuticals, Inc., which may influence their overall climate strategy. Historically, AMAG's emissions have varied, with Scope 1 emissions in 2019 reaching 104,400,000 kg CO2e and Scope 3 emissions peaking at approximately 1,200,000,000 kg CO2e. The company has not established any Science-Based Targets Initiative (SBTi) reduction targets or other formal climate pledges, indicating a potential area for future development in their sustainability efforts.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2018 | 2019 | 2021 | 2022 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 104,400,000 | 000,000,000 | 000,000,000 | - | - | 00,000,000 |
| Scope 2 | - | - | - | - | - | - |
| Scope 3 | - | - | 0,000,000,000 | - | - | 000,000 |
How Carbon Intensive is AMAG Pharmaceuticals, Inc.'s Industry?
How Carbon Intensive is AMAG Pharmaceuticals, Inc.'s Location?
AMAG Pharmaceuticals, Inc.'s Scope 3 Categories Breakdown
AMAG Pharmaceuticals, Inc.'s Scope 3 emissions, which decreased by 100% last year and decreased by approximately 100% since 2019, demonstrating supply chain emissions tracking. Their carbon footprint includes suppliers and value chain emissions, with Scope 3 emissions accounting for 1% of total emissions under the GHG Protocol, with "Purchased Goods and Services" representing nearly all of their reported Scope 3 footprint.
Top Scope 3 Categories
AMAG Pharmaceuticals, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
AMAG Pharmaceuticals, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
